Press Releases

June 5, 2014
Promedior Announces Presentation of Interim Phase 2 Data on PRM-151 in Myelofibrosis at the Upcoming Congress of European Hematology Association

May 30, 2014
Promedior to Present Positive Preliminary Phase 2 Data for PRM-151 in Myelofibrosis at ASCO Annual Meeting

May 15, 2014
Promedior Announces Presentation of Interim Phase 2 Data on PRM-151 in Myelofibrosis at ASCO

February 10, 2014
Promedior Appoints Richard Jack, PhD, as Chief Scientific Officer

January 8, 2014
Promedior Attains Patient Enrollment Milestone in Phase 2 Clinical Study of PRM-151 in Myelofibrosis

January 8, 2014
Promedior Appoints William Hodder as Vice President of Business Development

October 9, 2013
Promedior Initiates Phase 2 Clinical Study of PRM-151 in Myelofibrosis

June 19, 2013
Promedior Adds Howard J. Weisman to Board of Directors

May 22, 2013
Promedior Presents Encouraging Results from Clinical Study of PRM-151 in Patients with Idiopathic Pulmonary Fibrosis

May 16, 2013
Promedior to Present Clinical Data on Lead Drug Candidate, PRM-151, in Patients with IPF at the ATS 2013 Annual Meeting

February 27, 2013
Promedior to Present at the Cowen and Company 33rd Annual Health Care Conference

February 8, 2013
Promedior Announces Issuance of Two Additional U.S. Patents

February 5, 2013
Promedior to Present at the 2013 BIO CEO and Investor Conference

February 4, 2013
Promedior Announces Publication of Data from First-in-Human Trial of PRM-151 in Healthy Volunteers and Patients with Idiopathic Pulmonary Fibrosis

December 17, 2012
Promedior Opens New Office and Laboratories in Lexington, Mass.

October 15, 2012
Promedior Expands Series D Round of Financing to Total $24.5 Million to Advance Pipeline of Pentraxin-2 Therapeutics for Fibrotic Diseases

October 15, 2012
Promedior Appoints Elizabeth Trehu, M.D., as Chief Medical Officer

August 28, 2012
Promedior Receives Orphan Designation in Europe for Recombinant Human Pentraxin-2 for the Treatment of Idiopathic Pulmonary Fibrosis

May 15, 2012
Promedior Appoints Suzanne L. Bruhn, Ph.D., as President and Chief Executive Officer

May 7, 2012
Promedior Announces Presentation of Preclinical Data at ARVO Demonstrating that Pentraxin-2 Suppressed Fibrosis, Neovascularization, and Vascular Leakage

May 1, 2012
Promedior Announces Presentation of Data at ARVO Demonstrating that Pentraxin-2 Suppresses Fibrosis, Neovascularization, and Vascular Leak in Retinal Disease Models

March 7, 2012
Promedior Secures $21.5 Million in First Closing of Series D Financing to Expand and Advance Pipeline of Pentraxin-2 Therapeutics for Fibrotic Diseases

March 7, 2012
Promedior Receives U.S. Orphan Drug Designation for PRM-151 for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)

November 7, 2011
Promedior Presents Preclinical Data at AASLD Demonstrating That Pentraxin-2 Suppresses Liver Fibrosis and Has a Clear Hepatoprotective Effect

November 2, 2011
Promedior Announces Presentation of Preclinical Data at AASLD Demonstrating that Pentraxin-2 Suppresses Liver Fibrosis

May 16, 2011
Promedior Presents Clinical Data for PRM-151 (rhPTX-2) in Idiopathic Pulmonary Fibrosis at American Thoracic Society 2011

May 5, 2011
Promedior to Present Clinical Data for PRM-151 (rhPTX-2) in Idiopathic Pulmonary Fibrosis at ATS 2011

May 4, 2011
Promedior Announces Presentation of Preclinical Data at ARVO Demonstrating PRM-151 (rhPTX-2) Reduces Neovascularization in Retinal Diseases

April 19, 2011
Promedior Announces Presentation of Data at ARVO Demonstrating that PRM-151 (rhPTX-2) Suppresses Choroidal and Retinal Neovascularization

February 10, 2011
Promedior Announces Publication of New Research Demonstrating Pentraxin-2/SAP is a Potent Inhibitor of Pulmonary Fibrosis

February 10, 2011
Promedior Initiates Clinical Study of Anti-Fibrotic Therapeutic, PRM-151, in Patients with Idiopathic Pulmonary Fibrosis (IPF)

September 7, 2010
Promedior Announces Publication of New Research Demonstrating Pentraxin-2/SAP is a Potent Inhibitor of Asthma and Asthma-Induced Lung Fibrosis

September 7, 2010
Promedior Announces Initiation of Phase 2a Clinical Study of Anti-Fibrotic Therapeutic, PRM-151, in the Prevention of Post-Surgical Scarring in Glaucoma Patients

March 16, 2010
Promedior Closes $12 Million Series C Financing

November 4, 2009
Preclinical Studies Published in Science Translational Medicine Demonstrate that Therapeutic Administration of hSAP Inhibits Fibrosis

October 29, 2009
European Commission Grants Promedior's PRM-151 Orphan Drug Designation for the Prevention of Scarring Post Glaucoma Filtration Surgery

July 23, 2009
Promedior Initiates Phase 1 Clinical Trial of PRM-151, a Novel Compound for the Treatment of Fibrotic Diseases and Tissue Remodeling

January 22, 2009
Promedior's Fibrosis Program Featured at Keystone Symposia Conference

PTX-2

Crystal structure of human Pentraxin-2, a naturally occurring protein that is the foundation of Promedior's proprietary platform. Learn More >